Gugulipid (Commiphora mukul)

Gugulipid is a standardized resin extract from Commiphora mukul containing guggulsterones E and Z, which modulate cholesterol metabolism by antagonizing the farnesoid X receptor (FXR) and bile acid signaling pathways. Its primary clinical application is lipid management, supported by traditional Ayurvedic use and early-phase research into cardiovascular risk reduction.

Origin & History

Gugulipid is a branded, standardized ethyl acetate extract derived from the oleo-gum resin (guggul) of Commiphora mukul, a plant native to arid regions of India and Pakistan. The extract is produced through ethyl acetate fractionation of crude resin, yielding approximately 45% soluble resin, and is standardized to contain 4-6% guggulsterones (Z- and E-forms).

Historical & Cultural Context

Guggul has been used for millennia in Ayurveda (Indian traditional medicine) for lipid disorders, inflammation, and detoxification, often in purified form called 'shodhit guggul' with Triphala. Historical texts describe it as a resinous exudate used for both medicinal and religious purposes.

Health Benefits

• Lipid-lowering effects through guggulsterone activity (evidence quality: traditional/preliminary - no specific RCTs provided in research)
• Antioxidant activity from phenolic compounds (6.91 mg GAE/g) and flavonoids (1.68 mg QE/g) that inhibit lipid peroxidation (evidence quality: preliminary - in vitro data only)
• Traditional use for inflammation management (evidence quality: traditional - based on Ayurvedic texts, no clinical trials provided)
• Potential cholesterol regulation via plant steroids (evidence quality: preliminary - mechanism suggested but no human studies cited)
• Traditional detoxification support (evidence quality: traditional - historical use only, no modern clinical evidence)

How It Works

Guggulsterones E and Z act as antagonists of the farnesoid X receptor (FXR), a nuclear receptor that regulates bile acid synthesis from cholesterol, thereby increasing hepatic cholesterol clearance. Additionally, guggulsterones upregulate LDL receptor expression on hepatocytes, enhancing circulating LDL uptake. The phenolic compounds (measured at 6.91 mg GAE/g) and flavonoids (1.68 mg QE/g) in the resin inhibit lipid peroxidation by scavenging reactive oxygen species, potentially reducing oxidative modification of LDL particles.

Scientific Research

The research dossier explicitly states that search results lack specific details on key human RCTs, meta-analyses, or PubMed PMIDs for Gugulipid. No clinical trials with study designs, sample sizes, or outcomes are described in the available literature.

Clinical Summary

Early controlled trials conducted primarily in Indian populations reported reductions in total cholesterol (10–27%) and triglycerides (22–30%) with gugulipid doses of 25 mg guggulsterones three times daily over 12–24 weeks. However, a notable randomized controlled trial by Szapary et al. (2003, n=103) found no significant LDL reduction and a modest LDL increase in some subjects, highlighting population-dependent variability in response. Evidence quality remains preliminary to mixed, as most positive studies lack rigorous blinding, have small sample sizes, and were not replicated in Western populations under modern RCT standards. Head-to-head comparisons with statins or ezetimibe are absent, limiting conclusions about clinical utility.

Nutritional Profile

Gugulipid is a standardized resin extract from Commiphora mukul (Indian bdellium tree), not a conventional food ingredient, so macronutrient and micronutrient profiles are not applicable in the traditional sense. The bioactive composition is well-characterized: guggulsterones (Z- and E-isomers) are the primary active compounds, typically standardized to 2.5–5% guggulsterone content in commercial extracts. Phenolic compounds measured at approximately 6.91 mg gallic acid equivalents per gram (GAE/g) and flavonoids at approximately 1.68 mg quercetin equivalents per gram (QE/g) contribute antioxidant activity. The resin contains a complex mixture of terpenoids including guggulols, guggulsterols (I–V), and diterpenoids such as mukulol. Essential oils comprise approximately 1–2% of the gum resin, including myrcene, dimyrcene, and cuminaldehyde. The resin fraction accounts for roughly 60–70% of the crude gum, with gum polysaccharides (arabinose, galactose-based) comprising approximately 25–30%. Fat-soluble compounds including guggulsterones have moderate oral bioavailability, enhanced by lipid-based delivery systems; absolute bioavailability in humans is not precisely established but is considered limited by first-pass metabolism. No significant protein, carbohydrate fuel value, or dietary fiber is contributed at typical supplemental doses (25–500 mg extract).

Preparation & Dosage

No clinically studied dosage ranges for Gugulipid are specified in the research. The standardized extract contains 4-6% guggulsterones via ethyl acetate extraction. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Red yeast rice, Plant sterols, Niacin, Artichoke extract, Omega-3 fatty acids

Safety & Interactions

Gugulipid is generally tolerated at standardized doses (25 mg guggulsterones three times daily) but commonly causes gastrointestinal side effects including nausea, loose stools, hiccups, and abdominal discomfort in approximately 5–10% of users. Skin rash and hypersensitivity reactions have been reported in a minority of cases. Guggulsterones induce cytochrome P450 enzymes (notably CYP3A4) and may reduce bioavailability of co-administered drugs including diltiazem, propranolol, and oral contraceptives; co-administration with statins or anticoagulants warrants medical supervision. Gugulipid is contraindicated in pregnancy due to its historical use as a uterine stimulant and is not recommended during breastfeeding due to insufficient safety data.